bh009
Docetaxel
Zhuhai Beihai Biotech Co., LtdPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Docetaxel cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Docetaxel Zhuhai Beihai Biotech Co., Ltd | Phase 3 | B |
Catequentinib The First People's Hospital of Lianyungang | Phase 2 | CCC |
Nivolumab Peking University Cancer Hospital & Institute | Phase 2 | CCC |
Same molecule, other indications
bh009 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →